BeiGene plans to spend 'several hundred million dollars' on initial build-out of landmark US site

URLhttps://www.fiercepharma.com/manufacturing/beigene
Sourcehttps://www.fiercepharma.com
Date Published11/24/2021
Author NameJoseph Keenan
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name BeiGene Ltd.
Parent companyBeiGene
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
What product(s) and/or service(s) were outsourced domestically?Manufacturing
Year reshoring announced:2021
Year reshoring implemented or to be implemented:2024
Domestically, the work will be done:In-house
Country(ies) from which reshored:China
State(s) reshored to:NJ
If relevant, work nearshored to:-
Industry(ies):Chemicals, Cancer drugs
Product(s) reshoredCancer drugs
Find Reshoring Articles